Efficacy of a Recombinant Humanized Anti-IL-6 Receptor Monoclonal Antibody Compared to Hemoperfusion in Severe COVID-19 Pneumonia: Ambispective Cohort Study

被引：0
|
作者：
Thammavaranucupt, Kanin [1 ]
Jayanama, Kulapong [1 ]
Spanuchart, Ittikorn [2 ]
机构：
[1] Chakri Naruebodin Med Inst, Bang Phli, Thailand
[2] Mahidol Univ, Fac Med, Ramathibodi Hosp, Bangkok, Thailand
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO016
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [41] Catch-up growth in severe systemic-onset juvenile idiopathic arthritis: Long-term treatment with humanized anti-IL6 receptor monoclonal antibody
    Imagawa, T
    Miyamae, T
    Umebayashi, H
    Kurosawa, R
    Katakura, S
    Mori, M
    Nishimoto, N
    Yokota, S
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S91 - S92
  • [42] SHORT-TERM EFFICACY OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 12-WEEK RESULTS OF PHASE 2 AURORA STUDY
    Mazurov, V.
    Zotkin, Evgeniy
    Ilivanova, Elena
    Kropotina, Tatyana
    Plaksina, Tatyana
    Nesmeyanova, Olga
    Soroka, Nikolaj
    Kundzer, Alena
    Lutskii, Anton
    Dokukina, Ekaterina
    Chernyaeva, Ekaterina
    Ivanov, Roman
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 721 - 721
  • [43] Biological sex is associated with heterogeneous responses to IL-6 receptor inhibitor treatment in COVID-19—A retrospective cohort study
    Dan F. Stein
    Conor Foley
    Matt Byott
    Eleni Nastouli
    Gareth Ambler
    Nishkantha Arulkumaran
    Scientific Reports, 13
  • [44] Correspondence on 'Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study'
    Winkler, Martin Sebastian
    Korsten, Peter
    Binder, Claudia
    Tampe, Bjoern
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (08)
  • [45] Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib
    Mitev, Vanyo
    PHARMACIA, 2023, 70 (04) : 1177 - 1193
  • [46] Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
    Yuichi Maeda
    Toru Hirano
    Kosuke Ebina
    Ryota Hara
    Motomu Hashimoto
    Wataru Yamamoto
    Kosaku Murakami
    Takuya Kotani
    Kenichiro Hata
    Yonsu Son
    Hideki Amuro
    Akira Onishi
    Sadao Jinno
    Masaki Katayama
    Atsushi Kumanogoh
    Rheumatology International, 2021, 41 : 1233 - 1241
  • [47] Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
    Maeda, Yuichi
    Hirano, Toru
    Ebina, Kosuke
    Hara, Ryota
    Hashimoto, Motomu
    Yamamoto, Wataru
    Murakami, Kosaku
    Kotani, Takuya
    Hata, Kenichiro
    Son, Yonsu
    Amuro, Hideki
    Onishi, Akira
    Jinno, Sadao
    Katayama, Masaki
    Kumanogoh, Atsushi
    RHEUMATOLOGY INTERNATIONAL, 2021, 41 (07) : 1233 - 1241
  • [48] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF BCD-089, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY: RESULTS FROM THE FIRST-IN-HUMAN SINGLE DOSE ESCALATION STUDY IN HEALTHY VOLUNTEERS
    Khlyabova, P.
    Eremeeva, A.
    Lutckii, A.
    Dokukina, E.
    Chemyaeva, E.
    Ivanov, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 884 - 885
  • [49] Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study
    Borie, Raphael
    Savale, Laurent
    Dossier, Antoine
    Ghosn, Jade
    Taille, Camille
    Visseaux, Benoit
    Jebreen, Kamel
    Diallo, Abourahmane
    Tesmoingt, Chloe
    Morer, Lise
    Goletto, Tiphaine
    Faucher, Nathalie
    Hajouji, Linda
    Neukirch, Catherine
    Phillips, Mathilde
    Stelianides, Sandrine
    Bouadma, Lila
    Brosseau, Solenn
    Ottaviani, Sebastien
    Pluvy, Johan
    Le Pluart, Diane
    Debray, Marie-Pierre
    Raynaud-Simon, Agathe
    Descamps, Diane
    Khalil, Antoine
    Timsit, Jean Francois
    Lescure, Francois-Xavier
    Descamps, Vincent
    Papo, Thomas
    Humbert, Marc
    Crestani, Bruno
    Dieude, Philippe
    Vicaut, Eric
    Zalcman, Gerard
    PLOS ONE, 2020, 15 (12):
  • [50] A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as monotherapy for patients with neuromyelitis optica spectrum disorder (NMOSD)
    Traboulsee, A.
    Greenberg, B.
    Bennett, J. L.
    Szczechowski, L.
    Fox, E.
    Shkrobot, S.
    Yamamura, T.
    Terada, Y.
    Kawata, Y.
    Melia, A.
    Gianella-Borradori, A.
    Weinshenker, B. G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 730 - 731
12345